Managing Drug-Risk Information: What to Do with All Those New Numbers

From the New England Journal of Medicine

By Jerry Avorn, MD; Sebastian Schneeweiss, MD, ScD

SUMMARY: This NEJM Perspective by Avorn and Schneeweiss addresses the challenge of managing the growing volume of drug-risk data emerging from pharmacovigilance systems, post-market studies, and meta-analyses. The authors examine how clinicians and patients should interpret and act on the constant stream of new numbers — relative risks, absolute risks, number-needed-to-harm — generated by an increasingly active pharmacoepidemiology and drug safety literature. The piece considers both the problem of under-reaction to genuine safety signals and the problem of over-reaction to weak or uncertain findings, and offers a framework for how drug-risk information should be communicated and used in clinical decision-making. (Note: Full text paywalled; summary based on publicly available title, description, and field context.)

BACKGROUND: Post-market pharmacovigilance and pharmacoepidemiology research has generated a growing volume of drug-risk information, including safety signals of varying strength and clinical significance.

KEY FINDINGS: Not fully retrievable from publicly available text; article is paywalled. The piece examines how clinicians and patients should interpret and act on the constant flow of new drug-risk data, including how to distinguish meaningful safety signals from statistical noise.

IMPLICATIONS: Effective communication and interpretation of drug-risk information is essential for sound prescribing decisions, requiring frameworks that help clinicians and patients avoid both under-reaction to real hazards and over-reaction to uncertain findings.